What is the recommended antibiotic prophylaxis and peri‑procedural management for a patient undergoing endoscopic retrograde cholangiopancreatography (ERCP) with possible therapeutic intervention?

ERCP Peri-Procedural Management Plan

For patients undergoing ERCP with possible intervention, administer rectal NSAIDs (100 mg diclofenac or indomethacin) immediately before the procedure to all patients without contraindications, and reserve antibiotic prophylaxis for specific high-risk scenarios rather than routine use.

Post-ERCP Pancreatitis Prevention

Rectal NSAIDs are mandatory for PEP prevention and represent the single most important pharmacologic intervention 1. The evidence is unequivocal:

• Administer 100 mg diclofenac or indomethacin rectally immediately before ERCP to all patients without contraindications 1
• Both agents offer equivalent prophylactic efficacy 2
• This is a strong recommendation with moderate quality evidence 1

Prophylactic pancreatic stenting should be performed selectively in high-risk patients 1:

• Inadvertent guidewire insertion/opacification of the pancreatic duct
• Double-guidewire cannulation technique used
• Strong recommendation, moderate quality evidence 1

Avoid salvage pancreatic stenting in patients who have already developed post-ERCP pancreatitis 1.

Antibiotic Prophylaxis Strategy

The evidence on antibiotic prophylaxis has evolved significantly, creating tension between established guidelines and recent high-quality data. The 2020 ESGE guideline recommends against routine antibiotic prophylaxis 1, but two 2025 meta-analyses challenge this position 3, 4.

Current Guideline Position (2020)

The ESGE recommends against routine antibiotic prophylaxis before ERCP (strong recommendation, moderate quality evidence) 1.

When to Use Antibiotic Prophylaxis

Definite indications (weak recommendation, moderate quality evidence) 1:

• Anticipated incomplete biliary drainage (most important indication)
• Severely immunocompromised patients
• When performing cholangioscopy 1, 5

The Emerging Evidence Challenge

Two 2025 meta-analyses demonstrate significant benefits of prophylactic antibiotics in patients with biliary obstruction 3, 4:

The 2025 meta-analysis by 3 (5 RCTs, 1,154 patients) showed prophylactic antibiotics significantly reduced:

• Cholangitis (RR 0.44,95% CI 0.22-0.89)
• Bacteremia (RR 0.28,95% CI 0.13-0.58)
• Overall infectious complications (RR 0.35,95% CI 0.17-0.73)
• Benefits were most pronounced in patients with radiologically confirmed biliary obstruction

A concurrent 2025 meta-analysis 4 (11 RCTs, 2,105 patients) confirmed:

• Infectious complications reduced (RD -0.08,95% CI -0.14 to -0.02)
• Beta-lactam and cephalosporin antibiotics showed greatest effect (RD -0.10)
• Bacteremia rates reduced (RD -0.06)

Practical Antibiotic Algorithm

For patients with confirmed or suspected biliary obstruction undergoing ERCP:

First-line regimens (based on 6 ESCMID 2023 guidelines for perioperative prophylaxis):

• Ampicillin/sulbactam 3 g IV (redose every 2-4 hours intraoperatively)
• Piperacillin/tazobactam 3.375-4.5 g IV (redose every 2-4 hours intraoperatively)

Alternative regimens:

• Ciprofloxacin 400 mg IV (add anaerobic coverage if needed)
• Ertapenem 1 g IV (single dose, reserve for high-risk scenarios)
• Gentamicin 5 mg/kg IV (avoid with nephrotoxic drugs or renal dysfunction; add anaerobic coverage)

For penicillin allergy:

• Ciprofloxacin 400 mg IV with metronidazole if anaerobic coverage needed
• Gentamicin with anaerobic coverage

Critical Caveat on Antibiotic Evidence

The 2022 meta-analysis 7 found antibiotics reduced bacteremia but NOT cholangitis, sepsis, pancreatitis, or mortality. This creates clinical equipoise. The difference between the 2022 and 2025 analyses likely reflects:

• Different study inclusion criteria
• The 2025 analyses focused specifically on patients with biliary obstruction
• Improved study quality in more recent trials

Clinical decision-making: Given the 2025 evidence showing benefit specifically in biliary obstruction with radiologic confirmation, consider prophylactic antibiotics for all patients with documented biliary obstruction undergoing ERCP, despite the 2020 guideline recommendation against routine use. This represents an evidence-practice gap that clinicians should recognize.

Cholangioscopy-Specific Considerations

For peroral cholangioscopy, antibiotic prophylaxis reduces cholangitis risk (RR 0.46,95% CI 0.22-0.95), though the evidence is of very low certainty and borderline significance 5. Given the invasive nature of cholangioscopy and stone fragmentation, prophylactic antibiotics are reasonable 1, 5.

Anesthetic Management

Monitored anesthesia care (MAC) is recommended over general anesthesia for most patients undergoing ERCP, based on 2023 consensus guidelines 8. However, this recommendation is based on expert consensus rather than high-quality RCT evidence.

Coagulation Testing

Routine coagulation tests are not required prior to ERCP for patients not on anticoagulants and not jaundiced (weak recommendation, low quality evidence) 1.

Key Pitfalls to Avoid

1. Forgetting rectal NSAIDs - This is the most evidence-based intervention and should never be omitted without contraindication
2. Routine biliary sphincterotomy before stenting - Not recommended for single plastic stents or uncovered/partially covered metal stents 1
3. Excessive pancreatic duct manipulation - Number of pancreatic duct wire passages is a strong objective predictor of PEP 2
4. Withholding antibiotics in incomplete drainage scenarios - This remains an absolute indication regardless of guideline evolution